THA

American Joint Replacement Registry Releases 2022 Annual Report

Retrieved on: 
Friday, November 4, 2022
Patient, Annual report, 3D ultrasound, Academy, Growth, Education, Hospital, Multimedia, American Academy of Orthopaedic Surgeons, Database, Publication, American Academy, Shoulder, TKA, Fracture, AAOS, Hip, SER, MSTR, American Joint Replacement Registry, Collection, AANS, American Association of Neurological Surgeons, Registry, Robotics, Technology, ASR, Computer, Association, American Association, Health insurance, Dentistry, Prom, MD

ROSEMONT, Ill., Nov. 4, 2022 /PRNewswire/ -- The American Joint Replacement Registry (AJRR), the cornerstone of the American Academy of Orthopaedic Surgeons (AAOS) Registry Program, published its 2022 Annual Report on hip and knee arthroplasty procedural trends and patient outcomes today. The ninth annual report demonstrates an overall cumulative procedural volume growth of 14% compared to the previous year and includes over 2.8 million hip and knee procedures since 2012 from over 1,250 hospitals, ambulatory surgery centers (ASCs), and private practice groups submitting data.

Key Points: 
  • ROSEMONT, Ill., Nov. 4, 2022 /PRNewswire/ --The American Joint Replacement Registry (AJRR), the cornerstone of the American Academy of Orthopaedic Surgeons (AAOS) Registry Program , published its2022 Annual Reporton hip and knee arthroplasty procedural trends and patient outcomes today.
  • Some notable highlights in the 2022 Annual Report include:
    Patient-Reported Outcome Measures (PROMs) are increasingly being utilized to evaluate success of a hip or knee arthroplasty procedure.
  • The American Joint Replacement Registry (AJRR) , the Academy's hip and knee replacement registry, is the cornerstone of the AAOS's Registry Program, and the world's largest national registry of hip and knee joint replacement data by annual procedural count, with more than 2.8 million procedures contained within its database.
  • Additional registries include the Fracture & Trauma Registry ,the Musculoskeletal Tumor Registry (MsTR), the Shoulder & Elbow Registry (SER),and the American Spine Registry (ASR), a collaborative effort between the American Association of Neurological Surgeons (AANS) and the AAOS.

Akorn Announces Agreement to Sell its Branded Ophthalmic Products to Théa

Retrieved on: 
Friday, January 28, 2022
Growth, Hart–Scott–Rodino Antitrust Improvements Act, Willkie Farr & Gallagher, View, Patient, Sale, Ocular hypertension, Conjunctivitis, Timolol, LLC, Glaucoma, Nasal spray, Company, Ophthalmology, Industry, Greenhill & Co., Multimedia, Lidocaine, Hydrogen chloride, Pharmaceutical industry, Telescopic sight, Dorzolamide/timolol, Akorn

"I am pleased that we have reached this agreement with Tha.I believe they are well positioned and motivated to augment this ophthalmic franchise.

Key Points: 
  • "I am pleased that we have reached this agreement with Tha.I believe they are well positioned and motivated to augment this ophthalmic franchise.
  • Boothe continued: "This transaction will allow Akorn to focus on our core business of manufacturing and providing the marketplace with quality generic human and animal products.
  • Greenhill & Co., LLC is serving as the financial advisor and Willkie Farr & Gallagher LLP is serving as legal counsel to Akorn on the transaction.
  • Akorn develops, manufactures and markets specialty pharmaceuticals, including prescription, consumer health and animal health products.

New HSS Study Finds Hip Replacements on the Rise Among Adolescents Under 21 Years of Age

Retrieved on: 
Tuesday, November 9, 2021
Magnet, Health, Population, Weill Cornell Medicine, U.S. News & World Report, Elective surgery, JIA, MD, Education, News, Organization, Infection, Inflammatory arthritis, Hospital, The Hospital, Rheumatology, MBBS, American Nurses Credentialing Center, Hospital for Special Surgery, Database, Multimedia, Research, Aloha shirt, Necrosis, ACR, Osteoarthritis, American College of Rheumatology, Surgeon, Hip, Laboratory, Therapy, Long Island, Journal, Nursing, HSS, Physician, Juvenile idiopathic arthritis, Kid, American College, Medical device, Medicine, Dentistry, Health insurance

"We're doing a better job at treating these individuals so they don't develop end-stage joint damage.

Key Points: 
  • "We're doing a better job at treating these individuals so they don't develop end-stage joint damage.
  • For the study, Dr. Mehta and her colleagues used the Kids' Inpatient Database, a repository of information on patients under 21 years of age from approximately 4,200 hospitals in 46 states.
  • The mean age of young patients undergoing THA was just over 17 years and remained constant throughout the duration of the study.
  • As other studies have demonstrated in conditions like inflammatory arthritis, when hip replacements are performed by surgeons with significant experience, patients have better outcomes.

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Retrieved on: 
Thursday, September 16, 2021
Central nervous system, Therapy, CEO, Retinitis pigmentosa, Retina, RP, Patient, Company, Pharma, Neurological disorder, PDE6B, European Pharmaceutical Students' Association, Safety, IRD, Degenerative disease, Severe cognitive impairment, CNS, EU27, University, TOI, Partnership, AAV, Research, Pharmaceutical industry, Fine chemical, Vaccine

The agreement covers Coave's lead investigational gene therapy candidate CTx-PDE6b (formerly HORA-PDE6b) for patients with PDE6b-associated Retinitis Pigmentosa (RP), an inherited retinal disease (IRD).

Key Points: 
  • The agreement covers Coave's lead investigational gene therapy candidate CTx-PDE6b (formerly HORA-PDE6b) for patients with PDE6b-associated Retinitis Pigmentosa (RP), an inherited retinal disease (IRD).
  • "We are delighted to sign this agreement with Tha for CTx-PDE6b, our most advanced candidate, which represents an innovative new gene therapy for people with Retinitis Pigmentosa," said Rodolphe Clerval, CEO of Coave.
  • Under the terms of the agreement, Coave will receive an upfront payment and equity investment of 10 million from Tha.
  • Coave is also eligible to receive up to 65 million for achieving specified clinical development, regulatory and commercial milestones with CTx-PDE6b.

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Retrieved on: 
Thursday, September 16, 2021
European Union, Central nervous system, Therapy, CEO, Retinitis pigmentosa, Retina, RP, Patient, Union, Company, Pharma, Neurological disorder, PDE6B, European Pharmaceutical Students' Association, Safety, IRD, Degenerative disease, Severe cognitive impairment, CNS, EU27, University, TOI, Partnership, AAV, Research, Security (finance), Pharmaceutical industry, Fine chemical, Vaccine

PARIS, Sept. 16, 2021 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, has entered into an exclusive licensing, co-development and commercialization agreement with Théa, a leading European speciality Pharma focused on ophthalmology. The agreement covers Coave's lead investigational gene therapy candidate CTx-PDE6b (formerly HORA-PDE6b) for patients with PDE6b-associated Retinitis Pigmentosa (RP), an inherited retinal disease (IRD).

Key Points: 
  • The agreement covers Coave's lead investigational gene therapy candidate CTx-PDE6b (formerly HORA-PDE6b) for patients with PDE6b-associated Retinitis Pigmentosa (RP), an inherited retinal disease (IRD).
  • "We are delighted to sign this agreement with Tha for CTx-PDE6b, our most advanced candidate, which represents an innovative new gene therapy for people with Retinitis Pigmentosa," said Rodolphe Clerval, CEO of Coave.
  • Under the terms of the agreement, Coave will receive an upfront payment and equity investment of 10 million from Tha.
  • Coave is also eligible to receive up to 65 million for achieving specified clinical development, regulatory and commercial milestones with CTx-PDE6b.

Snoop Dogg to Headline Interactive Livestreamed Hip-Hop Festival, "THE RENAISSANCE: EP1," on VenewLive, the Livestream Platform Powered by Kiswe

Retrieved on: 
Monday, July 12, 2021
Musicians, Entertainers, Crips, Snoop Dogg, Dogg, Kiswe Mobile

One of the world's best known musicians across any genre, Snoop Dogg recently released his 18th studio album, Tha Streets 2 Tha Suites.

Key Points: 
  • One of the world's best known musicians across any genre, Snoop Dogg recently released his 18th studio album, Tha Streets 2 Tha Suites.
  • VenewLive is a Digital Live Performance Streaming Platform, powered by Kiswe, that delivers a unique immersive experience to global music fans, expanding viewership beyond physical venues.
  • Kiswe is the interactive video company that creates real-time live streams to engage digital audiences and unique communities around the world.
  • Kiswe is headquartered in New Jersey, USA and has offices in New York, Seoul, Hasselt and Singapore.

HSS Study Finds That MRI Identifies Adverse Tissue Reactions are Common in Asymptomatic Individuals After Hip Resurfacing Arthroplasty

Retrieved on: 
Thursday, July 8, 2021
Surgery, Medical specialties, Clinical medicine, Prosthetics, Pelvis, Hip replacement, Arthroplasty, Hip resurfacing, THA, Derek McMinn, Minimally invasive hip resurfacing

Potter and Koff and HSS colleagues prospectively evaluated 206 patients (243 hip replacements) at least one year after having hip resurfacing arthroplasty or total hip replacement.

Key Points: 
  • Potter and Koff and HSS colleagues prospectively evaluated 206 patients (243 hip replacements) at least one year after having hip resurfacing arthroplasty or total hip replacement.
  • The researchers compared results for patients who received hip resurfacing arthroplasty (HRA) with patients who received ceramic-on-polyethylene and metal-on-polyethylene total hip replacements.
  • During the study, MRI identified adverse local tissue reactions in 25 percent of patients who had hip resurfacing arthroplasty.
  • Patients who received hip resurfacing arthroplasty had a significantly larger volume of joint tissue reaction on MRI, a nearly five-times-higher risk of having tissue complications than patients who had a ceramic-on-polyethylene total hip replacement.

Nevakar Announces Formation Of Ophthalmic Company, Vyluma

Retrieved on: 
Tuesday, May 25, 2021
Medication, Pharmaceutical industry, Ophthalmic, Natural sciences

BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ --Nevakar Inc. ("Nevakar"), a privately held biopharmaceutical company, today announces the establishment of Vyluma Inc., a newly formed company with a focus on the development and commercialization of therapies to treat ophthalmic diseases.

Key Points: 
  • BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ --Nevakar Inc. ("Nevakar"), a privately held biopharmaceutical company, today announces the establishment of Vyluma Inc., a newly formed company with a focus on the development and commercialization of therapies to treat ophthalmic diseases.
  • At inception Vyluma will operate as a wholly owned subsidiary of Nevakar Inc.
    Vyluma will focus on first-in-class and best-in-class ophthalmic pharmaceutical therapies, with an emphasis on refractive errors.
  • With the establishment of Vyluma, our ophthalmic portfolio will have a dedicated team of professionals focused on assuring Vyluma meets its commitment to patients, prescribers, shareholders and other key constituents."
  • Nevakar Inc. is a privately held, late-stage biopharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas.

Computer-guided surgery with Smith+Nephew's hip replacement implants shown to significantly improve survivorship and increase patient satisfaction compared to conventional surgery

Retrieved on: 
Wednesday, April 28, 2021
Prosthetics, Medicine, Hip replacement, Pelvis, Patient satisfaction, THA, Health care

This gives me supreme confidence that I\'m performing the most accurate THA procedure for my patient and ensuring the best possible result.

Key Points: 
  • This gives me supreme confidence that I\'m performing the most accurate THA procedure for my patient and ensuring the best possible result.
  • "\nRI.HIP NAVIGATION technology is designed tohelp maximise accuracy and reproducibility by delivering patient-specific component alignment a critical factor for surgeons when assessing individual THA cases.
  • "RI.HIP NAVIGATION combined with our best-in-class POLAR3 THA construct may considerably improve implant survivorship and help patients return to living their Life Unlimited.
  • Computer guided total hip arthroplasty is associated with a reduced risk of revision and increased patient satisfaction.

OrthoGrid Systems, Inc. Announces Launch of New OrthoGrid Hip Software Application for Direct Anterior Approach Total Hip Arthroplasty

Retrieved on: 
Tuesday, February 23, 2021
Medical specialties, Prosthetics, Medicine, Clinical medicine, Pelvis, Hip replacement, THA, Arthroplasty, Implant

The new OrthoGrid Hip is the latest version of OrthoGrid System's patented, distortion-correcting, implant-agnostic, intraoperative-alignment technology for direct anterior hip total hip arthroplasty (DAA THA) offered on the company's AI-enabled digital platform.

Key Points: 
  • The new OrthoGrid Hip is the latest version of OrthoGrid System's patented, distortion-correcting, implant-agnostic, intraoperative-alignment technology for direct anterior hip total hip arthroplasty (DAA THA) offered on the company's AI-enabled digital platform.
  • In addition, the new OrthoGrid Hip enables surgeons to get precise leg length and hip offset measurements to achieve their desired biomechanical alignment.
  • "We are thrilled to bring this latest version of our OrthoGrid Hip software to market," says Richard Boddington, co-founder and co-CEO of OrthoGrid.
  • OrthoGrid Hip is an image-processing software indicated to assist in the positioning of Total Hip Replacement components.